Elyse Stock - 10 Jan 2022 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Role: Chief Medical Officer
Signature: /s/ George Clark, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 10 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 12 Jan 2022, 20:10:06 UTC
Previous filing: 07 Jan 2022
Next filing: 03 Oct 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BHVN	Common Shares	Options Exercise	$0	+937	+21%	$0.000000	5,374	10 Jan 2022	By Spouse
holding	BHVN	Common Shares						11,090	10 Jan 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BHVN	Restricted Share Unit Award	Options Exercise	$0	+937	+93700%	$0.000000	938	10 Jan 2022	Common Shares	937		By Spouse	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted share unit represents the contingent right to receive one common share of the Issuer.
F2	The reporting person was granted 3,750 restricted share units on January 8, 2020, vesting in four equal installments on January 8, 2020, 2021, 2022 and 2023, subject to the reporting person's continued service with the Issuer at each vesting date.
F3	Not applicable.